Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

By J. O’Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, C. Rocha, I. C. Koo, B. Sherman, C. Bradley. New England Journal of Medicine, 2011

754 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (2012, background): “Cells deficient for BRCA1 or BRCA2 are highly sensitive to PARP1 inhibitors (Bryant et al, 2005; Farmer et al, 2005), which are currently in use in clinical trials for cancer patients with BRCA1 and BRCA2 germline mutations (Gelmon et al, 2011; O’Shaughnessy et al, 2011).”
An overview of triple-negative breast cancer (2016, result): “Initial studies on iniparib were encouraging [147], but later studies were unable to confirm either”